Pan-RAS-IN-1 NEW
| Price | $73 | $98 | $147 |
| Package | 1mg | 2mg | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Pan-RAS-IN-1 | CAS No.: 1835283-94-7 |
| Purity: 98.57% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Pan-RAS-IN-1 |
| Description | Pan-RAS-IN-1 is an inhibitor of pan-Ras. It disrupts the interaction of Ras proteins and their effectors. |
| In vitro | Pan-RAS-IN-1 is cytostatic, possibly due to pan-RAS inhibition at some concentrations. Pan-RAS-IN-1 is evaluated in primary T cell acute lymphoblastic leukemia (T-ALL) cells. Selective lethality is observed, with mutant NRAS cells retaining only 20%-40% viability after 5 μM treatment. Pan-RAS-IN-1 binds to KRasG12D-GppNHp with an affinity of less than 20 μM. Pan-RAS-IN-1 binds to Ras proteins and exhibits lethality in cells partially dependent on the expression of Ras proteins. The potency of pan-RAS-IN-1 correlates with the degree of dependency on the mutated isoform over a 5-fold concentration range [1]. |
| In vivo | Pan-RAS-IN-1-treated mice show decreased tumor pERK levels compared with vehicle-treated mice. Pan-RAS-IN-1 administration causes inhibition of tumor growth over 15 days of treatment. A modest increase in cleaved caspase-3 is also observed, showing that pan-RAS-IN-1 has the capacity to induce caspase activation in this model[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 50 mg/mL (69.67 mM) |
| Keywords | PanRASIN1 | inhibit | Pan-RAS-IN-1 | Ras | Pan RAS IN 1 | Inhibitor |
| Inhibitors Related | Adagrasib | BI-2493 | Vemurafenib | Ketoconazole | SKLB-163 | MRTX1133 | Salirasib | sodium lauroyl-α-hydroxyethyl sulfonate | RMC-6236 | (S)-(-)-Perillyl alcohol | CASIN | Sotorasib |
| Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Anti-Ovarian Cancer Compound Library | Inhibitor Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Compound Library | Anti-Liver Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/1g |
VIP1Y
|
Wuhan Circle Star Chem-medical Technology Co.,Ltd
|
2025-01-17 | |
| $1520.00/25mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-22 | |
| $1530.00/25mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-10-28 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY